GM cuts 50% of Cruise staff after ending robotaxi business

GM cuts 50% of Cruise staff after ending robotaxi business


A robot car of the General Motors subsidiary Cruise is on a test drive.

Andrej Sokolow | picture alliance | Getty Images

General Motors is laying off roughly half of its employees who remain at its discontinued Cruise robotaxi business.

The plans come two months after GM said it would no longer fund Cruise after spending more than $10 billion on the robotaxi unit since acquiring it in 2016.

“Today, Cruise shared the difficult decision to part ways with approximately 50% of its workforce,” Cruise said in an emailed statement. “We are grateful for their passion and contributions to help us reach this stage, and our focus is on supporting them into their next chapter with severance packages and career support.”

About 88% of remaining employees are in engineering or related roles, according to the company.

Layoffs were expected at Cruise, however executives previously declined to speculate on the amount. The job cuts were announced in conjunction with the Detroit automaker announcing the completion of Cruise becoming a wholly-owned subsidiary within GM.

Cruise had nearly 2,300 employees as of the end of last year.

“While not an easy decision, we are focused on combining efforts with General Motors to accelerate autonomy at scale on personal autonomous vehicles,” Cruise said.

GM cited the increasingly competitive robotaxi market, capital allocation priorities and the considerable time and resources necessary to grow the business as reasons for its decision.

This is breaking news. Please refresh for updates.



Source

FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More
Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war
Business

Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war

Toyota Motor Corp. vehicles bound for shipment at the Port of Nagoya in Tokai, Aichi Prefecture, Japan, on Tuesday, April 29, 2025. Toru Hanai | Bloomberg | Getty Images DETROIT — Toyota Motor, Hyundai Motor and Chinese automakers such as Chery face the most potential impact of non-domestic automakers from the U.S.-Israel war with Iran, […]

Read More